Travere Therapeutics, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Travere Therapeutics, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2011 | Feb 29, 2012 | $0 | May 24, 2012 |
| FY2011 | Feb 28, 2011 | $0 | May 24, 2012 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $490.73M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $233.18M | Feb 19, 2026 |
| FY2023 | Dec 31, 2023 | $45.06M | Feb 20, 2024 |
| FY2023 | Sep 30, 2023 | $37.10M | Feb 20, 2024 |
| FY2023 | Jun 30, 2023 | $32.20M | Feb 20, 2024 |
| FY2023 | Mar 31, 2023 | $30.89M | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | $29.34M | Feb 20, 2024 |
| FY2023 | Sep 30, 2022 | $28.08M | Feb 20, 2024 |
| FY2023 | Jun 30, 2022 | $28.63M | Feb 20, 2024 |
| FY2023 | Mar 31, 2022 | $23.41M | Feb 20, 2024 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($25.55M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($321.55M) | Feb 19, 2026 |
| FY2023 | Dec 31, 2023 | ($90.17M) | Feb 20, 2024 |
| FY2023 | Sep 30, 2023 | $150.74M | Feb 20, 2024 |
| FY2023 | Jun 30, 2023 | ($85.63M) | Feb 20, 2024 |
| FY2023 | Mar 31, 2023 | ($86.33M) | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | ($65.82M) | Feb 20, 2024 |
| FY2023 | Sep 30, 2022 | ($69.66M) | Feb 20, 2024 |
| FY2023 | Jun 30, 2022 | ($67.03M) | Feb 20, 2024 |
| FY2023 | Mar 31, 2022 | ($75.97M) | Feb 20, 2024 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($62.82M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($323.83M) | Feb 19, 2026 |
| FY2023 | Dec 31, 2023 | ($94.23M) | Feb 20, 2024 |
| FY2023 | Sep 30, 2023 | ($92.59M) | Feb 20, 2024 |
| FY2023 | Jun 30, 2023 | ($103.95M) | Feb 20, 2024 |
| FY2023 | Mar 31, 2023 | ($97.37M) | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | ($86.70M) | Feb 20, 2024 |
| FY2023 | Sep 30, 2022 | ($82.60M) | Feb 20, 2024 |
| FY2023 | Jun 30, 2022 | ($78.53M) | Feb 20, 2024 |
| FY2023 | Mar 31, 2022 | ($71.98M) | Feb 20, 2024 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $7.50M | Feb 23, 2023 |
| FY2019 | Dec 31, 2019 | $140.96M | Feb 24, 2020 |
| FY2019 | Dec 31, 2018 | $123.76M | Feb 24, 2020 |
| FY2019 | Dec 31, 2017 | $78.17M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $70.82M | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $50.43M | Jul 6, 2018 |
| FY2016 | Dec 31, 2014 | $47.80M | Mar 1, 2017 |
| FY2015 | Dec 31, 2013 | $7.08M | Feb 26, 2016 |
| FY2013 | Dec 31, 2012 | $662.5K | Jul 9, 2015 |
| FY2012 | Dec 31, 2011 | $353.0K | Sep 16, 2013 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $337.20M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $264.12M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $265.54M | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | $197.52M | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | $126.28M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $135.80M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $128.95M | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $103.65M | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $101.33M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $91.94M | Feb 26, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $37.78M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($237.48M) | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | ($280.02M) | Feb 19, 2026 |
| FY2024 | Dec 31, 2022 | ($186.29M) | Feb 21, 2025 |
| FY2023 | Dec 31, 2021 | ($14.79M) | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | ($42.74M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | ($58.21M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | ($24.96M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $7.40M | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | ($3.44M) | Feb 26, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | $668.0K | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | $191.0K | Feb 20, 2024 |
| FY2023 | Dec 31, 2021 | $5.10M | Feb 20, 2024 |
| FY2022 | Dec 31, 2020 | $6.77M | Feb 23, 2023 |
| FY2021 | Dec 31, 2019 | $195.0K | Feb 24, 2022 |
| FY2020 | Dec 31, 2018 | $727.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2017 | $887.0K | Feb 24, 2020 |
| FY2018 | Dec 31, 2016 | $1.43M | Feb 26, 2019 |
| FY2017 | Dec 31, 2015 | $22.0K | Jul 6, 2018 |
| FY2016 | Dec 31, 2014 | $663.0K | Mar 1, 2017 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $605.19M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $594.13M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $788.91M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $672.59M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $776.63M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $607.44M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $604.80M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $709.16M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $520.35M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $525.28M | Jul 6, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $490.36M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $535.05M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $588.10M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $629.73M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $474.52M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $396.23M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $383.60M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $390.91M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $227.21M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $217.52M | Jul 6, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $114.83M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $59.08M | Feb 19, 2026 |
| FY2025 | Dec 31, 2023 | $200.81M | Feb 19, 2026 |
| FY2025 | Dec 31, 2022 | $42.85M | Feb 19, 2026 |
| FY2024 | Dec 31, 2021 | $302.11M | Feb 21, 2025 |
| FY2023 | Dec 31, 2020 | $211.21M | Feb 20, 2024 |
| FY2022 | Dec 31, 2019 | $221.20M | Feb 23, 2023 |
| FY2021 | Dec 31, 2018 | $318.25M | Feb 24, 2022 |
| FY2020 | Dec 31, 2017 | $293.13M | Mar 1, 2021 |
| FY2019 | Dec 31, 2016 | $307.77M | Feb 24, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | $800.0K | Feb 21, 2025 |
| FY2024 | Dec 31, 2023 | $800.0K | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $800.0K | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $900.0K | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $900.0K | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $936.0K | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $936.0K | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $936.0K | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | $936.0K | Jul 6, 2018 |
| FY2016 | Dec 31, 2015 | $936.0K | Mar 1, 2017 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($1.47B) | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | ($1.45B) | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | ($1.13B) | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | ($1.01B) | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | ($765.97M) | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | ($585.88M) | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | ($416.44M) | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | ($270.02M) | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | ($177.66M) | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | ($113.06M) | Jul 6, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $93.04M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | $58.54M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | $58.18M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | $61.69M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | $165.75M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $84.77M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | $62.44M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | $102.87M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | $99.39M | Feb 26, 2019 |
| FY2018 | Dec 31, 2016 | $41.00M | Feb 26, 2019 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 19, 2026 |
| FY2023 | Dec 31, 2023 | (1) | Feb 20, 2024 |
| FY2023 | Sep 30, 2023 | 1 | Feb 20, 2024 |
| FY2023 | Jun 30, 2023 | (1) | Feb 20, 2024 |
| FY2023 | Mar 31, 2023 | (1) | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Feb 20, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Feb 20, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Feb 20, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Feb 20, 2024 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | (4) | Feb 19, 2026 |
| FY2023 | Dec 31, 2023 | (1) | Feb 20, 2024 |
| FY2023 | Sep 30, 2023 | 1 | Feb 20, 2024 |
| FY2023 | Jun 30, 2023 | (1) | Feb 20, 2024 |
| FY2023 | Mar 31, 2023 | (1) | Feb 20, 2024 |
| FY2023 | Dec 31, 2022 | (1) | Feb 20, 2024 |
| FY2023 | Sep 30, 2022 | (1) | Feb 20, 2024 |
| FY2023 | Jun 30, 2022 | (1) | Feb 20, 2024 |
| FY2023 | Mar 31, 2022 | (1) | Feb 20, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 90.92M | Feb 19, 2026 |
| FY2025 | Dec 31, 2024 | 87.45M | Feb 19, 2026 |
| FY2024 | Dec 31, 2023 | 75.37M | Feb 21, 2025 |
| FY2023 | Dec 31, 2022 | 64.29M | Feb 20, 2024 |
| FY2022 | Dec 31, 2021 | 62.49M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 52.25M | Feb 24, 2022 |
| FY2020 | Dec 31, 2019 | 43.09M | Mar 1, 2021 |
| FY2019 | Dec 31, 2018 | 41.39M | Feb 24, 2020 |
| FY2018 | Dec 31, 2017 | 39.37M | Feb 26, 2019 |
| FY2017 | Dec 31, 2016 | 37.91M | Jul 6, 2018 |